BIIB Biogen Inc
Market Cap
41.51B
Day’s Range
52W Range
Volume (3M)
1.2M
Price-Earnings Ratio
14.69
Revenue
9.65B
Biogen Inc Latest News
FDA accepts NDA filing by Biogen and Sage for zuranolonePharmaceutical Business Reviewabout 6 hours ago
FDA accepts NDA and grants priority review of Zuranolone from Sage Therapeutics, BiogenExpress Pharmaabout 10 hours ago
Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive'Benzingaabout 22 hours agoAbout Biogen Inc
Biogen, Inc. is a biopharmaceutical company founded in 1978. It specialises in designing medications targeting neurological and neurodegenerative disorders. Headquartered in Cambridge, Massachusetts, Biogen operates internationally in the Americas, Europe, Australia, and Asia. The company is listed on the NASDAQ under the ticker BIIB. Broaden your investment scope by buying BIIB stock.
Show More9.6K
Employees
Cambridge, Massachusetts, US
HQ
1978
Founded
Christopher A. Viehbacher, CPA
CEO
Upcoming Earnings
15
FEB
REPORTS
Biogen Inc Q4 2022 earnings report is expected to be released before market open
Consensus
Moderate Buy
Price Target
338.00
Get insight into a company's sustainability using ESG (environmental, social, and governance) scores.
0
100
54
Medium
Industry
Avg. 45
62
Environment
62
Social
42
Governance
People Also Bought
REGN Regeneron Pharmaceuticals -2.20% 
VRTX Vertex Pharmaceuticals Incorporated -0.36% 
ZTS Zoetis -0.77% 
AZN AstraZeneca PLC ADR -0.35% 
BMRN BioMarin Pharmaceutical Inc -1.24%